Doug Kerr MD PhD, Biogen-Idec’s Director of Neurodegenerative Research, talks dexpramipexole, the lessons learned and the development of future ALS medicines in the clinic going forward. Read more: http://blogs.als.net/post/ALS-clinical-trials-powering-forward.aspx